Cutaneous dermatomyositis in the era of biologicals

  title={Cutaneous dermatomyositis in the era of biologicals},
  author={Natalie Andrews Wright and Ruth Ann Vleugels and Jeffrey P. Callen},
  journal={Seminars in Immunopathology},
Dermatomyositis (DM) is a systemic inflammatory condition characterized by cutaneous and muscle findings, in addition to potential involvement of other organ systems. A distinct subtype of DM exists that is categorized by cutaneous findings with absent or minimal muscle involvement, referred to as clinically amyopathic dermatomyositis or dermatomyositis sine myositis. A variety of topical, immunosuppressive, and immunomodulatory therapies have been utilized to treat cutaneous DM. The advent of… Expand
Dermatomyositis: clinicopathological correlations.
  • P. Sena, A. Gianatti, D. Gambini
  • Medicine
  • Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia
  • 2018
The specific histological findings that can be found in the different presentations of the disease are discussed and the most common differential diagnoses are discussed. Expand
Infliximab improved the refractory cutaneous involvement in a patient with dermatomyositis
A case of amyopathic dermatomyositis associated with rheumatoid arthritis in which both joint and skin symptoms were successfully treated with infliximab is reported. Expand
Characterizing clinicopathological and immunohistochemical findings in dermatomyositis panniculitis
  • A. Kuhn
  • Medicine
  • Journal of the European Academy of Dermatology and Venereology : JEADV
  • 2018
Analyzing clinicopathological and immunohistochemical findings to provide a better characterization of DM panniculitis is studied, finding several factors such as environmental triggers, genetic predisposition and immuneand non-immune-mediated mechanisms play a role in the development of DM. Expand
The skin in autoimmune diseases-Unmet needs.
There is a high unmet need for new therapeutic strategies focusing on skin involvement in systemic autoimmune diseases, and innovative designs of randomized controlled trials with validated skin scores are warranted to develop new therapeutic Strategies for patients with cutaneous manifestations. Expand
Rapidly progressive interstitial lung disease in a patient with anti-MDA5-positive amyopathic dermatomyositis
This book aims to provide a history of the use of antibiotics in the Faroe Islands and some examples of their applications in the treatment of infectious diseases and rheumatology. Expand
Geospatial Correlation of Amyopathic Dermatomyositis With Fixed Sources of Airborne Pollution: A Retrospective Cohort Study
Investigation of the geospatial distributions of DM and subtypes, classic DM (CDM) and clinically amyopathic DM (CADM), and their associations with airborne pollutants found prevalence of CADM, but not CDM, is geospatially correlated with fixed sources of airborne emissions. Expand


Successful treatment of cardiac involvement in dermatomyositis with rituximab.
A 25year-old female with dermatomyositis and cardiac involvement resistant to disease modifying anti-rheumatic drugs and anti-tumor necrosis factor-alpha is presented, demonstrating a remarkable clinical and laboratory response to rituximab. Expand
Rituximab in the treatment of refractory dermatomyositis.
B-cell depletion therapy with rituximab used alone or in combination with other immunosuppressive therapies may be a viable option in patients with dermatomyositis as well as other autoimmune diseases refractory to current therapies. Expand
Cutaneous Dermatomyositis: An Updated Review of Treatment Options and Internal Associations
The therapies available as well as the internal associations with dermatomyositis are discussed, including a mixture of patients with idiopathic inflammatory myopathy and do not utilize a validated assessment tool for measuring cutaneous disease responses. Expand
Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases.
Three patients suffering from classic dermatomyositis (juvenile and adult-onset) with prominent recalcitrant skin manifestations are described and rituximab, a monoclonal anti-CD20 antibody is given, achieving a response with minimal side effects. Expand
Treatment of early and refractory dermatomyositis with infliximab: a report of two cases
Two patients with refractory DM who were treated with infliximab are reported, and their presentation, clinical course, treatment, and outcomes are described. Expand
Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease
Intravenous immunoglobulins (IVIg) are recommended for corticoresistant or corticodependant DM, but only a few cases of IVIg use in DM with isolated skin involvement have been reported. Expand
Successful treatment for conventional treatment-resistant dermatomyositis-associated interstitial lung disease with adalimumab
A patient with DM-associated ILD who had poor response to conventional therapies and successfully treated with adalimumab is described, which indicates that more effective and less toxic therapies are needed. Expand
Case reports of etanercept in inflammatory dermatoses.
Cases in which etanercept was administered to ameliorate the symptoms of acute and chronic dermatologic conditions, including Hailey-Hailey disease, severe psoriasis, dermatomyositis, and subacute cutaneous lupus erythematosus are reported. Expand
Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis.
The case described herein is unique in that anti-TNF-induced autoimmune disease occurred in a patient with existing arthritis since childhood and recurred with rechallenge, adding further evidence to support the existence of anti-tumor necrosis factor-induced DM. Expand
Tumor necrosis factor inhibitor-associated dermatomyositis.
4 cases of dermatomyositis that developed or were exacerbated by exposure to the TNF inhibitors etanercept and adalimumab indicate that TNF inhibitor use can be associated with either induction or exacerbation of dermatomeositis. Expand